EPSRC logo

Details of Grant 

EPSRC Reference: EP/X038181/1
Title: Manufacturing research hub for a sustainable future: Vaccines for pandemic preparedness
Principal Investigator: Micheletti, Professor M
Other Investigators:
Mauri, Dr M M Winterburn, Dr J Green, Dr C
Bracewell, Professor DG Wren, Professor B Stonehouse, Professor N
Dikicioglu, Dr D Biswas, Professor S Gilbert, Professor SC
Frank, Dr S Murdan, Dr S Parker, Dr B
Researcher Co-Investigators:
Project Partners:
AstraZeneca Baseimmune Limited Catalent Pharma Solutions
Centre for Process Innovation CPI (UK) Croda (Group) Incepta Vaccine Ltd.
LGC Ltd MCI Sante Animale Micropore Technologies
Phenotypeca Ltd Sartorius Corporate GmbH SpyBiotech Ltd
Synthace Limited UK BioIndustry Association (BIA) VABIOTECH
Department: Biochemical Engineering
Organisation: UCL
Scheme: Standard Research
Starts: 01 September 2023 Ends: 31 August 2030 Value (£): 12,295,896
EPSRC Research Topic Classifications:
Bioprocess Engineering Drug Formulation & Delivery
Manufact. Enterprise Ops& Mgmt Manufacturing Machine & Plant
EPSRC Industrial Sector Classifications:
Manufacturing Pharmaceuticals and Biotechnology
Related Grants:
Panel History:  
Summary on Grant Application Form
The Covid-19 pandemic continues to take a huge toll - an estimated 6.3m people have died including 178,000 in the UK. Globally 1.6bn students have missed school, 250m people will be pushed into extreme poverty and economic losses are estimated at £12tr. History shows that epidemic and pandemic threats constantly emerge, whilst SARS-CoV-2 continues to mutate as it becomes endemic. It is clear that major losses could be prevented by sustained domestic investment in public health. Work undertaken within Vax-Hub1 on responsive technologies and accelerated quality control methods enabled rapid development and manufacture of the ChAdOx1 vectored vaccine against SARS-CoV-2 (licensed for emergency use in December 2020 via a non-profit partnership with AstraZeneca). Over 2.9bn doses have now been released in 180 countries. The UK had a leading role during the pandemic and the proposed Hub builds on this success to advance novel research on a broader range of technologies. Working closely with stakeholders, Vax-Hub will enable the UK to be better prepared for the next pandemic.

This investment into The Future Vaccine Manufacturing Hub will enable our vision to make the UK the global centre for vaccine discovery, development and manufacture. The Vaccine Manufacturing Hub brings together a world-class multidisciplinary team with decades of cumulative experience in all aspects of vaccine design and manufacturing research. This Hub will bring academia, industry, not-for-profit organizations and policy makers together to propose radical change in vaccine development and manufacturing technologies, building on a technological innovation culture.

The Hub will enhance future vaccine manufacturing through (i) de-risked manufacture of new vaccines by strategically innovating for a selected range of the most promising platform technologies (established and novel/disruptive); (ii) developing manufacturing options that improve the product quality and so immunogenicity; (iii) streamlined manufacturing process development with novel responsive solutions and advanced digitalisation strategies; (iii) a focus on enhancing stability and needle-free administration routes so they become a reality within the lifetime of the Hub. The proposed Hub would be the natural location for early-stage research before projects are transferred to a GMP manufacturing facility.

The work focuses on development of improved vaccine platforms which can be flexible enough to be used for multiple product manufacture. These improved vaccine technologies are used as case studies to test rapid and responsive development tools to create a whole process mimicking vaccine manufacture, which could be easily and quickly deployed in case of epidemic/pandemic scenario. Finally the research focuses on standard and novel adjuvants to make mucosal delivery a reality, thus allowing alternative route to injection for mass administration.

The Hub will establish the UK as the global centre for end-to-end vaccine research and manufacture. Additionally, vaccines should be considered a national security priority, as it is evident that diseases do not respect international boundaries, thus this work into capacity building and rapid response is a significant advantage. The impact of this Hub will be felt internationally, as the UK reaffirms its leadership in Global Health and works to ensure that the outputs of this Hub reach the global community and the most vulnerable, especially children.

Key Findings
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Potential use in non-academic contexts
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Description This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Date Materialised
Sectors submitted by the Researcher
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Project URL:  
Further Information:  
Organisation Website: